Cervarix Approval History
- FDA approved: Yes (First approved October 16th, 2009)
- Brand name: Cervarix
- Generic name: human papillomavirus bivalent (types 16 and 18) vaccine, recombinant
- Dosage form: Injection
- Company: GlaxoSmithKline
- Treatment for: Human Papillomavirus Prophylaxis
Cervarix (human papillomavirus bivalent (types 16 and 18) is a is a preventative cervical cancer vaccine for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 in girls and young women (aged 10-25).
Development History and FDA Approval Process for Cervarix
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.